Nkarta, Inc., was incorporated in Delaware in July 2015. The Company is a clinical-stage biopharmaceutical company dedicated to the development of allogeneic, off-the-shelf engineered natural killer (" NK ") cell therapies for the treatment of patients with autoimmune diseases or hematological malignancies. The company was founded on the belief that engineered NK cell therapies can transform patients' lives by providing therapies that are clinically meaningful, widely accessible and not subject to safety concerns associated with other cell therapy approaches. 

NKTX

NKTX Profile